RaySearch Laboratories’ stock fell sharply today after the company revealed preliminary financials for the second quarter of 2026 that missed market expectations. The shares dropped 27.4% to trade at 162 SEK following the disclosure, marking one of the steepest intraday declines the Stockholm-listed oncology software developer has seen in recent memory.
The preliminary figures point to a year-over-year decline in net sales, with organic growth reported at -8%. Management also flagged a steep reduction in operating profit compared with the prior-year period. Company executives said the shortfall in revenue was largely a result of several U.S. deals being pushed back in timing - delayed rather than canceled - which deferred revenue recognition tied to those transactions.
Investors reacted negatively to the scale of the shortfall. The share price slid to its lowest level in more than a year, briefly touching a 52-week low of 160.1 SEK as selling pressure overwhelmed buyers. The broader market provided little shelter; the OMX Stockholm 30 slipped modestly on the session, leaving RaySearch to bear the brunt of its own earnings disappointment.
These preliminary results extend a difficult period for the company. Revenue contraction was already evident in the first quarter of 2026, and the newly released Q2 data indicate that top-line weakness continued into the second quarter. That pattern raises questions about the timing and strength of a recovery in North America, a key market for the company’s RayStation and RayCare treatment planning and oncology information platforms.
There was, however, a more constructive datapoint in the report: order intake for Q2 2026 improved on a year-over-year basis. That suggests ongoing demand for the company’s products. But because accounting for those sales depends on deal closings, postponements of contract completions in the U.S. have translated directly into delayed revenue recognition, leaving near-term results vulnerable to timing effects.
Market participants also noted the absence of offsetting catalysts. No significant analyst upgrades or positive macro developments emerged to counteract the earnings shock, which contributed to the abrupt move lower. Until management provides clarity on when the deferred American contracts are expected to convert into recognized revenue, investor sentiment is likely to remain cautious ahead of the final Q2 report.
Context for investors
- Preliminary Q2 2026 results show net sales falling year-over-year with organic growth of -8%.
- Operating profit retreated sharply versus the prior-year period.
- Management attributed the revenue shortfall to a cluster of U.S. deals being postponed, delaying revenue recognition.